Inclusion Criteria:

• Patients with a histologic diagnosis of:
  • Newly diagnosed;
  • Progressive;
  • Relapsed lymphoma (any NHL HL, or CLL histology) who are initiating or changing therapy (chemotherapy, radiotherapy, or clinical trial/ investigational agent), or who have measurable disease and are being expectantly monitored. Patients whose lymphoma is in remission and who are being monitored expectantly are eligible as a separate cohort.
• Age > 18 years.
• May be s/p autologous or allogeneic bone marrow transplant.
• Ability to understand and willing to sign a written informed consent document.
• Patients with a histologic diagnosis of relapsed lymphoma or multiple myeloma who are scheduled to undergo CAR T cell therapy (up to 25 patients).
• Newly diagnosed, untreated DLBCL patients confirmed by pathologic review. 

​​Exclusion Criteria:

• Patients already receiving any investigational agents or chemotherapy at time of baseline sample collection.
• Medical illnesses with potential suppressive or activating impact on immune and bowel function as judged by the investigator.                               
• Patients with CNS disease or lymphoma related to prior chemotherapy (new DLBCL cohort only).
• Patients with hemoglobin level of 8 or below.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 3/17/23. Questions regarding updates should be directed to the study team contact.